Healthcare
Harmony Biosciences Holdings, Inc.(HRMY)
Live Price
Offline$34.46
-2.10% today
1Y Change
+9.12%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.81B
- Revenue Growth
- +21.5%
- EPS Growth
- +7.8%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Harmony Biosciences Holdings, Inc. (HRMY) is a Healthcare stock with a market cap of $1.81B and listed on NASDAQ. The stock last traded around $34.46 and up 9.1% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +21.5%, EPS growth of +7.8%, a dividend yield of 0.0%. What stands out right now is revenue +21.5%, EPS +7.8%, free cash flow +59.1% with operating margin 24.0% and ROIC 13.9%. Valuation is more restrained than many high-expectation growth names at P/E 11.4 and price/sales 2.1. Stock Foundry combines HRMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.5% vs +7.6% peer median
Operating Margin
Above sector median
+24.0% vs +19.4% peer median
P/E
Below sector median
11.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +21.5% and EPS at +7.8%, with operating margin around 24.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +1.4% | -6.8% | -0.7% |
2026 Feb 24, 2026 | -54.8% | +0.0% | +0.3% | -3.9% |
2025 Nov 4, 2025 | -5.4% | +2.1% | +7.4% | +20.4% |
Benchmark Edge
HRMY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HRMY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HRMY Max Drawdown
-34.49%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HRMY and SPY.
Company Overview
Harmony Biosciences Holdings, Inc.
NASDAQ Global Market
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
- Leadership
- Jeffrey Dayno
- IPO Date
- Aug 19, 2020
- Employees
- 268
- Street Address
- 630 West Germantown Pike
- Mailing
- Plymouth Meeting, PA, 19462
- Region
- Plymouth Meeting, PA, US
- Reporting Currency
- USD
- Investor Line
- 484 539 9800
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 11.4
- EV/EBITDA
- 5.2
- Price/Sales
- 2.1
- Price/Book
- 2.1
Growth
- Revenue
- +21.5%
- EPS
- +7.8%
- Free Cash Flow
- +59.1%
Profitability
- Gross Margin
- 77.2%
- Operating Margin
- 24.0%
- Net Margin
- 18.3%
- ROE
- 19.8%
- ROIC
- 13.9%
Balance Sheet
- Debt/Equity
- 0.28
- Current Ratio
- 3.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.